EMA Authorised: Renagel (sevelamer) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA authorised Renagel (sevelamer) for hyperphosphatemia in patients with chronic kidney disease on dialysis, with Sanofi Winthrop Industrie as the marketin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• Renagel (sevelamer)

Snippet

Status: Authorised. Therapeutic area: Renal Dialysis;Hyperphosphatemia. MAH: Sanofi Winthrop Industrie. Decision date: 13/01/2025